Cargando…
Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors- Are We Doing Better? A Systematic Review on Treatment Disparity
Coronary artery disease (CAD) is a significant contributor to mortality in America. A common risk factor of CAD is hyperlipidemia. Treatment guidelines of hyperlipidemia are well established. Statins are the cornerstone of treating hyperlipidemia. New medications such as proprotein convertase subtil...
Autores principales: | Singh, Chetana, Valero, Danel J, Nisar, Javariya, Trujillo Ramirez, Jose I, Kothari, Karisma K, Isola, Sasank, San Hernandez, Aleyda M, Gordon, Domonick K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667606/ https://www.ncbi.nlm.nih.gov/pubmed/33209524 http://dx.doi.org/10.7759/cureus.10965 |
Ejemplares similares
-
Multiple Sclerosis and Serotonin: Potential Therapeutic Applications
por: San Hernandez, Aleyda M, et al.
Publicado: (2020) -
The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
por: Parikh, Riya R, et al.
Publicado: (2022) -
Neurocognitive Impairment in Cardiovascular Disease Patients Taking Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Systematic Review
por: Shahid, Rabia, et al.
Publicado: (2022) -
Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
por: Wu, Qingyu, et al.
Publicado: (2022) -
Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9
por: Melendez, Quantil M., et al.
Publicado: (2020)